抗磷脂抗体综合征复发性流产治疗研究进展

Advances in the Treatment of Antiphospholipid Combined Recurrent Abortion

复发性自然流产(RSA)发病率不断上升,是一种影响有生育需求女性身心健康的生殖并发症,随着国家三胎政策的实施,越来越多的女性受到复发性流产的困扰,其家庭幸福指数及新生命的延续受到严重威胁。研究发现一半以上的复发性流产可能与免疫因素有关,其中抗磷脂抗体异常是最相关的因素之一。抗凝治疗及免疫抑制及调节治疗可有效提高复发性流产合并抗磷脂抗体异常患者的成功分娩率,然而,是否需要及如何实施治疗仍然是最大的医疗热点。本综述的目的是通过查阅文献总结目前抗磷脂综合征复发性流产的治疗方法,为临床治疗提供参考。The rising incidence of recurrent spontaneous abortion (RSA) is a kind of reproductive complications that affects the physical and mental health of women with reproductive needs. With the implementation of the country’s three-child policy, more and more women are suffering from recurrent abortions, and its family happiness index and the continuation of new life are seriously threatened. Studies have found that more than half of recurrent miscarriages may be related to immune factors, among which abnormal antiphospholipid antibodies are one of the most relevant factors. Anticoagulation therapy, immunosuppression and regulation therapy can effectively improve the successful delivery rate of patients with recurrent abortion complicated with abnormal antiphospholipid antibodies. However, whether and how to implement treatment is still the biggest medical hotspot. The purpose of this review is to summarize the current treatment methods of recurrent abortion in antiphospholipid syndrome by reviewing the literature, and to provide reference for clinical treatment.